Tens of thousands of cancer patients across England are poised to benefit from a revolutionary one-minute injection, marking a significant advancement in NHS cancer care. This new subcutaneous jab is set to drastically reduce the time patients spend receiving vital anti-cancer treatment, freeing up valuable clinical time for healthcare professionals.
The injection, primarily for patients receiving Phesgo – a combination of pertuzumab and trastuzumab – replaces an intravenous infusion that typically takes between two to seven minutes to administer. The new method delivers the same life-saving medication in just 60 seconds, allowing patients to spend less time in treatment centres and more time recovering at home.
NHS England has confirmed that this accelerated treatment will be rolled out across various trusts, with many already beginning the transition. This initiative is expected to improve the patient experience by making treatments quicker and less disruptive, while also enabling oncology teams to manage their workload more efficiently.
The move comes as healthcare services continue to innovate to meet patient needs and improve efficiency. While specific regional breakdowns of the rollout are not immediately available, the nationwide implementation suggests a broad impact across all areas of England, from major metropolitan centres to more rural communities.
Met Office data indicates that the coming weeks will see variable weather across the UK, with some regions experiencing mild conditions and others facing cooler temperatures and potential rainfall. Patients attending appointments are advised to check local forecasts and dress appropriately, ensuring comfort during travel and any waiting times. Practical safety advice includes ensuring adequate hydration, especially for those undergoing treatment, and planning travel to and from appointments with potential weather disruptions in mind.